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Background: Although advanced esophageal squamous-cell carcinoma (ESCC) is treated using a multidisciplinary
approach, outcomes remain unsatisfactory. The microenvironment of cancer cells has recently been shown to
strongly influence the biologic properties of malignancies. We explored the effect of supernatant from esophageal
fibroblasts on the cell growth and chemo-resistance of ESCC cell lines.
Methods: We used 22 ESCC cell lines, isolated primary human esophageal fibroblasts and immortalized fibroblasts.
We first examined cell proliferation induced by fibroblast supernatant. The effect of supernatant was evaluated to
determine whether paracrine signaling induced by fibroblasts can influence the proliferation of cancer cells. Next,
we examined the effects of adding growth factors HGF, FGF1, FGF7, and FGF10, to the culture medium of cancer
cells. These growth factors are assumed to be present in the culture supernatants of fibroblasts and may exert a
paracrine effect on the proliferation of cancer cells. We also examined the intrinsic role of HGF/MET and FGFs/FGFR
in ESCC proliferation. In addition, we examined the inhibitory effect of lapatinib on ESCC cell lines and studied
whether the fibroblast supernatants affect the inhibitory effect of lapatinib on ESCC cell proliferation. Finally, we
tested whether the FGFR inhibitor PD-173074 could eliminate the rescue effect against lapatinib that was induced
by fibroblast supernatants.
Results: The addition of fibroblast supernatant induces cell proliferation in the majority of cell lines tested. The
results of experiments to evaluate the effects of adding growth factors and kinase inhibitors suggests that the
stimulating effect of fibroblasts was attributable in part to HGF/MET or FGF/FGFR. The results also indicate diversity
in the degree of dependence on HGF/MET and FGF/FGFR among the cell lines. Though lapanitib at 1 μM inhibits
cell proliferation by more than 50% in the majority of the ESCC cell lines, fibroblast supernatant can rescue the
growth inhibition of ESCC cells. However, the rescue effect is abrogated by co-treatment with FGFR inhibitor.
Conclusion: These results demonstrate that cell growth of ESCC depends on diverse receptor tyrosine kinase
signaling, in both cell-autonomous and cell-non-autonomous manners. The combined inhibition of these signals
may hold promise for the treatment of ESCC.
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Currently, esophageal cancer is the eighth most common
cancer in the world [1,2]. Esophageal cancer remains one
of the least studied and most lethal malignancies [3].
Squamous-cell carcinoma accounts for 92.5% of all pri-
mary esophageal tumors in Japan and other Asian coun-
tries [4-6], while adenocarcinoma is the most prevalent
histologic type of esophageal cancer in western countries
[7]. Since the overall incidence and mortality of esophageal
squamous-cell carcinoma (ESCC) is lower than other can-
cers such as breast cancer, colorectal cancer and lung can-
cer in western countries [8], biological studies of ESCC
have been lagging behind. Advanced ESCC is treated using
a multidisciplinary approach, including surgery, chemo-
therapy, and radiotherapy, but outcomes remain unsatis-
factory [9-12].
Cancers are the end-product of accumulated effects of
many genetic alterations, and the specific combination of
changes is reflected in the unique characteristics of each
tumor. The microenvironment of cancer cells has recently
been shown to strongly influence the biologic properties of
cancer [13].
A tumor consists of a dynamic mixture of tumor cells,
fibroblasts, endothelial cells, immune cells and extracel-
lular matrix. In many solid tumors, the stroma has been
recognized to be important in promoting tumor prolif-
eration, invasion, metastasis, and chemo-resistance
[14,15]. The proliferation of fibroblasts is frequently
seen in the invasive portion of a malignant tumor and
tumors with significant proliferation of those cells are
associated with a poor prognosis in colorectal cancers,
breast cancers and lung cancers [16-18]. In ESCC, pre-
vious reports described that stromal fibroblasts have an
important role in angiogenesis [19] and tumor differen-
tiation [20]. Fibroblasts are associated with cancer cells
at all stages of cancer progression, and their production
of growth factors, chemokines and extracellular matrix
facilitates the angiogenic recruitment of endothelial
cells and pericytes [21].
Hepatocyte growth factor (HGF) regulates cell growth,
cell motility, and morphogenesis by activating a tyrosine
kinase signaling cascade after binding to the c-Met recep-
tor [22]. HGF is secreted by mesenchymal cells including
fibroblasts and promotes invasion of ESCC cells [23].
Fibroblast Growth Factors (FGFs) have been implicated
in the regulation of cell differentiation, proliferation, mi-
gration and survival in many different cell types [24]. The
biological activities of FGFs are mediated by FGF recep-
tors (FGFR). FGFR2 has two different isoforms that are
designated FGFR2 IIIb and FGFR2 IIIc; the former is par-
ticularly localized in epithelial cells with growth induced
by FGF-1, 3, 7, 10 and the latter binds FGF-1, 2, 4, 6, 9
and is expressed mainly in mesenchymal cells [25,26].
FGFR2 positive tumor fibroblasts may provide cancercells with a suitable microenvironment to promote can-
cer development and progression [27].
Lapatinib is a dual tyrosine kinase inhibitor of epidermal
growth factor receptor (EGFR) and human EGFR-2
(HER2) tyrosine kinase domains [28,29]. Recently lapatinib
has been evaluated for the treatment of not only breast
cancer [30,31] but also gastric cancer [32] and ESCC [33].
To date, however, few studies have evaluated the role of
stromal fibroblasts in ESCC. In this study, we focused on
the relationship between ESCC cells and fibroblasts, the
main component of cancer stroma. We prepared in vitro
experimental systems to evaluate the interactions between
ESCC and fibroblasts and clarify the mechanisms by which
fibroblasts control proliferation of ESCC cells at the mo-
lecular level. We also studied the effects of various tyrosine




PHA-665752 and PD-173074 were obtained from Tocris
Bioscience (Bristol, UK). Lapatinib was obtained from Bio
Vision (Milpitas, USA). Recombinant human HGF, recom-
binant human FGF1, 7, and 10 were obtained from R & D
System (Minneapolis, USA). Stock solutions of PHA-
665752, PD-173074 and lapatinib were prepared in
dimethyl sulfoxide and stored at −80°C until use. Stock so-
lutions of HGF and FGFs were prepared in phosphate-
buffered saline (PBS) and stored at −80°C until use.
Esophageal squamous cell lines
We used 22 esophageal squamous cell lines: TE-1, TE-4,
TE-5, TE-6, TE-8 TE-9, TE-10, TE-11, TE-14, TE-15, and
EC-GI-10 were obtained from RIKEN Cell Bank (Tsukuba,
Japan), while KYSE30, KYSE50, KYSE70, KYSE140, KYS
E150, KYSE170, KYSE180, KYSE220, KYSE270, T.T, and
TTN were obtained from Health Science Research Re-
sources Bank (Osaka, Japan). All cancer cell lines were
maintained in RPMI 1640 supplemented with 10% fetal bo-
vine serum (FBS, Autogen Bioclear), glutamine, 100units/ml
penicillin, and 100 μg/ml streptomycin, in a humidified at-
mosphere with 5% CO2.
Fibroblasts
Primary human esophageal fibroblasts designated as
HEF75 [34], HEF2111, HEF1173 and cancer associated
fibroblasts designated as HECAF2111 were isolated from
human esophagus tissues which were resected in the De-
partment of Surgery, Jichi Medical University Hospital.
The patient from whom the tissue was obtained had not
received neoadjuvant chemotherapy or radiation therapy.
The study was approved by the Jichi Medical University
Ethics Committee and written informed consent was ob-
tained from the patient.
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twice in PBS and cut into 1–2 mm3 pieces. Several pieces
were placed in a six-well plate, and the explants cultured for
48 hours in DMEM (Dulbecco’s modified Eagle’s medium;
Invitrogen) supplemented with 10% FBS, antibiotics, and
glutamine at 37°C in a humidified atmosphere with 5% CO2.
After removing the explants and non-adherent cells, the
remaining cells were incubated for 1–2 weeks. The adherent
cells were then trypsinized and passaged into a new culture
flask at a ratio of 1:3 for further expansion. The cells were
used for subsequent experimental study after the third
passage.
Human lung-derived fibroblasts, HFL-III, obtained from
RIKEN Cell Bank, were also used in some experiments.
Immortalization of esophageal fibroblasts
Immortalized fibroblasts, designated as HFE75-hTERT
(human telomerase reverse transcriptase), were described
previously [34]. In brief, in accordance with the protocol
of Lipofectamin 2000 Reagent (Invitrogen Co., Ltd.), plas-
mid DNA encoding hTERT (pCLXSN-hTERT), a kind gift
from Dr. T. Kiyono, National Cancer Research Institute,
Japan [37], and pVSV-G were co-transfected into the
GP2-293 cell line. After 48 hours, the culture supernatant
including the retrovirus was added to fibroblasts to induce
transduction. Selection was performed with G418 (Genet-
icin®, Invitrogen) 48 hours after transduction. In this study,
cells between the 20th and 25th passage after viral transduc-
tion were used. Immortalized human esophageal fibroblasts
were designated as human esophageal fibroblast (HEF) 75-
human telomerase reverse transcriptase (HEF75-hTERT).
Antibodies
Rabbit polyclonal anti-phospho-Akt, anti-phospho-Erk
antibodies (Cell Signaling Technology, Danvers, MA) and
goat polyclonal anti-beta actin (Santa Cruz Biotechnology,
Santa Cruz, CA) were used in this study.
Gene expression profile
A comprehensive gene expression analysis was performed
using an oligonucleotide microarray (GeneChip Human
Genome U133A, Affymetrix, Santa Clara, CA) as described
previously [38]. The data discussed in this publication have
been deposited in NCBI’s Gene Expression Omnibus [39]




Cells were lysed in a lysis buffer consisting of 20 mmol/L
Tris–HCl (pH7.4), 150 mmol/L NaCl, 50 mmol/L NaF, and
1 mmol/L Na3VO4 with a cocktail of proteinase inhibitors.
After sonication, lysates were immersed in water at 98°C
for five minutes and cleared by centrifugation. Proteinconcentrations were determined using the DC Protein Assay
kit (BioRad). For Western blot analysis, equal amounts of
protein samples were size-separated on 8% polyacrylamide
gels and electroblotted onto a nitrocellulose membrane.
Nonspecific binding was blocked by immersion of the mem-
branes for 20 minutes in 5% skim milk in Tris-buffer saline
at room temperature.
Membranes were washed with Tris-buffer saline buffer
containing 0.1% Tween 20, incubated for one hour at room
temperature with primary antibodies, washed, and then
reacted with peroxidase-conjugated secondary antibodies.
The antigen was detected using ECL Western Blotting De-
tection Reagents (Amersham) following the manufacturer’s
instructions.
Cell proliferation assay
Cell viability was measured using the Cell Counting Kit
(CCK) 8 assay (Dojindo, Tokyo, Japan) according to the
manufacturer’s instructions. ESCC cells (4-10×103 cells)
were plated in 96-well microtiter plates. After 24 hours,
a supernatant of fibroblasts or growth factors (HGF,
FGF1, FGF7, and FGF10), was added to the wells as
appropriate.
The fibroblast supernatant was prepared by incubating
HEF75 or HEF75-hTERT in DMEM containing 0.1%FBS
for 12 hrs. The prepared supernatant was diluted at 1×, 1/
2×, 1/10×, 1/100×, and 1/1000× with 0.1%FBS +DMEM
and added to the ESCC cells. The final concentrations of
the growth factors were: 20 ng/ml, 10 ng/ml, 2 ng/ml,
0.2 ng/ml and 0.02 ng/ml for HGF; 10 ng/ml, 1 ng/ml,
0.1 ng/ml, 0.01 ng/ml and 0.001 ng/ml for FGF1; 40 ng/ml,
20 ng/ml, 2 ng/ml, 0.2 ng/ml, 0.02 ng/ml for FGF7; and
20 ng/ml, 10 ng/ml, 1 ng/ml, 0.1 ng/ml and 0.01 ng/ml for
FGF10.
After the addition of fibroblast supernatant or growth
factors, cells were incubated for four days at 37°C. For
inhibition experiments, cells were incubated in the pres-
ence of 1 μM of lapatinib (a dual inhibitor of epidermal
growth factor receptor and human epidermal growth
factor receptor 2), PHA-665752 (MET inhibitor), PD-
173074 (FGFR inhibitor), or 0.1% of dimethyl sulfoxide
(DMSO, negative control).
At the end of the four-day incubation, the absorbance
of each well at 450 nm was measured with a reference at
630 nm using a BIO-RAD model 680XR microplate
reader (Bio-Rad, Hercules, CA).
The percentage of cell viability was calculated by following
formula:%cell viability = (mean absorbance in test wells)/
(mean absorbance in control well) ×100. Results were plot-
ted as cell viability versus log10 (concentration of reagents).
To describe the blocking effect of PHA-665752 and PD-
173074 on the growth promoting effect of fibroblast super-
natant, a blunting index was calculated by the formula:
blunting index (%) = 100-(fold change in the presence of
Saito et al. BMC Cancer  (2015) 15:82 Page 4 of 12PHA-665752 (or PD-173074) and fibroblast supernatant/
fold change in the presence fibroblast supernatant alone) ×
100.
Enzyme-linked immunosorbent assay (ELISA)
Human HEF75, HEF75-hTERT, and some cancer cells in a
confluent state were cultured for 24 hours in RPMI/DMEM
containing 0.1%FBS, and the supernatant concentration
was measured by Quantikine® human FGF 7 immunoassay
or human HGF immunoassay (R&D Systems). Measure-
ments were performed in accordance with the manufac-
turer’s instructions.
Statistical analysis
Analysis of variance was used to compare mean values of
continuous variables among three or more groups, and P-
values were calculated. When the P-value was less thanFigure 1 Proliferative responses of ESCC cell lines to HEF75 and HEF75-h
show significantly increased cell proliferation until a one-half dilution, as compa
on one-way analysis of variance. Dunnet’s test was used for comparison with th
absorbance. (B) Supernatants from HEF75-hTERT also significantly stimulate the
responses of 22 ESCC cell lines to fibroblast supernatants. With normal esophag
in 12 cell lines. With immortalized esophageal fibroblast (HEF75-hTERT) superna
proliferation rate compared to controls is shown by a graduated color scale (low
of the proliferation assay after addition of HEF 75 or HEF75-hTERT as compared
with control is highlighted in green. The data shown are the mean values of tw0.05 and the null hypothesis was rejected, Dunnett’s test, a
method for post hoc comparison, was used to compare
the groups. The Jmp9 (SAS Institute Inc., Cary, North
Carolina, USA) statistical software package was used for
analysis.
Results
Effect of fibroblast supernatant on ESCC cell proliferation
The effect of fibroblast supernatant was evaluated to de-
termine whether paracrine signaling induced by fibro-
blasts can influence the proliferation of cancer cells.
Using the cell count assay, fibroblast supernatant from
HEF75 and HEF75-hTERT increased cell proliferation by
1.25 fold or more in 12 and 21 of 22 cell lines, respect-
ively (Figure 1).
When proliferation assays were performed using cul-
ture supernatant obtained from fibroblasts establishedTERT fibroblast supernatants. (A) KYSE30, KYSE220, TE-11, and TE-14
red with the control group. For each cell line, the P- value is less than 0.001
e control group, and P-values were calculated. The Y axis indicates the
proliferation of KYSE220, TTN, TE-11 and TE-14 cell lines. (C) Proliferative
us fibroblast supernatant (HEF75), 1.25-fold or higher proliferation is induced
tant, 1.25-fold or higher proliferation is induced in 21 cell lines. The
er panel). Fold change by HEF75 or HEF75-hTERT is the ratio of the results
with the control. A 1.25 fold or higher increase in proliferation as compared
o or more independent experiments for each cell line.
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derived fibroblasts (HFL-III), generally similar trends are
observed (data not shown). These findings imply that
growth factors or cytokines secreted by fibroblasts play an
important role in cancer cell proliferation.
Gene expression
We hypothesized that HGF and FGFs secreted by fibroblasts
may be responsible for the stimulatory effect of fibroblast
supernatant [13,23,24,27,40]. To test this hypothesis, we
studied gene expression profile data to determine if fibro-
blasts and ESCC cells expressed the ligands (HGF and FGFs)
and their receptors (MET and FGFR1-4). The relevantFigure 2 Gene expression data of the components of the HGF/MET a
lines. (A) The gene expression of HGF and FGF1-10 in esophageal fibrobla
in four types of esophageal fibroblasts, three derived from normal esophag
(HEcaF2111). The bar graph shows the expression levels of the indicated g
cell lines. MET and FGFR2 are highly expressed in the majority of ESCC cell
genes. The expression data were normalized with the Affymetrix MAS5.0 alresults are shown in Figure 2. Relatively high expression
levels of FGF2, FGF7 and HGF are observed with fibroblasts
established from tumor (HECAF2111) and three types of fi-
broblasts established from normal tissue (HFF75, HEF1173,
and HEF2111). Analysis of the cancer cell lines shows a vari-
able, but widespread expression of MET and FGFR2, which
are receptors for HGF and FGF7, respectively, across the
panel of ESCC cell lines (Figure 2).
Extrinsic and intrinsic roles of HGF/MET and FGFs/FGFR in
ESCC cell proliferation
Next, we examined the effects of adding growth factors
HGF, FGF1, FGF7, and FGF10, to the culture medium ofnd FGF/FGFR systems in esophageal fibroblasts and ESCC cell
sts is shown. High expression of FGF2 and FGF7 is consistently found
us (HEF75, HEF1173, and HEF2111) and one derived from tumor
enes. (B) The gene expression levels of MET and FGFR1-4 in 22 ESCC
lines. The bar graph shows the expression levels of the indicated
gorithm with target intensity of 100.
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the culture supernatants of fibroblasts, may exert a paracrine
effect on the proliferation of cancer cells [23,24,27,40]. The
results are shown in Figures 3 and 4. HGF stimulates the
proliferation of two cell lines (KYSE170 and KYSE220) byFigure 3 Changes in the proliferation of esophageal cancer cell lines
cell lines are shown as bar graphs. Proliferation is significantly induced by H
and TE-14 is induced by FGF1 at a concentration of 1 ng/mL or higher. Sig
concentration of 2 ng/mL or higher. For each cell line, the P-value is less th
for comparison with the control group, and P-values were calculated. Themore than 1.36 fold, but the stimulatory response is less
marked in the other 20 cell lines. FGF1, FGF7, and FGF10
induce the proliferation of four, four, and two cell lines by
1.5 fold or more, respectively. In particular, FGF7 induces
the proliferation of eight cell lines by a factor of 1.25 fold orafter addition of HGF and FGF1, 7, and 10. Data for representative
GF in KYSE220 and KYSE170 cell lines. Significant proliferation of TE-11
nificant proliferation of KYSE50 and TE-15 is induced by FGF7 at a
an 0.001 on one-way analysis of variance. Dunnet’s test was used
Y axis indicates the absorbance.
Figure 4 Growth stimulation by HGF and FGFs and growth inhibition by MET inhibitor and FGFR inhibitor. HGF stimulates the proliferation of
two cell lines (KYSE170 and KYSE220) by more than 1.36 fold, while the addition of FGFs (1, 7, and 10) induces a 1.25-fold or higher growth stimulation
in 11 cell lines. MET inhibitor (PHA-665752) inhibits proliferation by 25% or more in six cell lines. FGFR inhibitor (PD-173074) inhibits proliferation by
25% or more in six cell lines, three of which are also growth inhibited by MET inhibitor.
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cell lines by 1.25 or more. We also examined the intrinsic
role of HGF/MET and FGFs/FGFR in ESCC proliferation.
Cell proliferation assays were performed after adding 0.1%
of DMSO (control), PD-173074 (MET inhibitor), or PD-
173074 (FGFR inhibitor). As compared with control, PHA-
665752 and PD-173074 each inhibit cell proliferation by
25% or more in six cell lines (Figure 4).
These results indicate that cell proliferation of many
ESCC cell lines is dependent on HGF/MET and FGF/
FGFR either in an extrinsic or intrinsic manner. These
experiments also indicate diversity in the degree of de-
pendence on HGF/MET and FGF/FGFR among the cell
lines tested, with more cell lines exogenously dependent
on FGF/FGFR than on HGF/MET.
Western blot analysis
Both Akt and ERK1/2 participate in the biological effects of
growth factors [41-43]. The ERK signaling cascade is re-
ported to control the proliferation of multiple cell types in
response to growth factor treatment [44,45]. In contrast,
Akt signaling is best known for mediating cell survival [43].
Cell lines with proliferation induced by fibroblast superna-
tants (TE-11, TE-14, and KYSE220) were selected. Western
blot analysis was performed to assess the phosphorylation of
AKT and ERK1/2 6 hours after adding supernatant. As
shown in Figure 5, treatment with fibroblast supernatantmarkedly up-regulates p-ERK protein levels in all three
cell lines tested (Figure 5). p-AKT protein levels are also
clearly up-regulated by supernatants in two cell lines
(KYSE220 and TE-11), and slightly upregulated in one cell
line (TE-14).
Effects of PHA-665752 (MET inhibitor) and PD-173074
(FGFR inhibitor) on cell proliferation induced by fibroblast
supernatant
To investigate the relative contribution of HGF/MET
and FGFs/FGFR to the stimulatory effect of fibroblast
supernatant, we tested the effect of PD-173074 (FGFR
inhibitor) and PHA-665752 (MET inhibitor) treatment
on cell proliferation induced by fibroblast supernatant.
The results are shown in Figure 6. When the MET
(HGF receptor) inhibitor PHA-665752 was added to
fibroblast culture supernatants at a final concentration
of 1 μM, stimulation by fibroblast supernatant is mod-
estly blunted in KYSE220, but not significantly affected
in TE-14. In contrast, when the FGFR inhibitor (PD-
173074) is added to fibroblast culture supernatants at a
final concentration of 1 μM, the opposite pattern is ob-
served. Stimulation by fibroblast supernatant is markedly
blunted by FGFR inhibitor in TE-14, but the blunting ef-
fect of FGFR inhibitor is less obvious in KYSE220. We
calculated the blunting index for each inhibitor, as de-
scribed in the Methods section. A high blunting index
Figure 5 Changes in the phosphorylation of ERK and AKT after adding fibroblast (HEF -75hTERT) culture supernatant. In representative cell lines
(TE-11, TE-14, and KYSE220), we examined the phosphorylation of ERK and AKT six-hours after the addition of supernatant. Both p-ERK and p-AKT levels are
markedly up-regulated by treatment with fibroblast supernatant, though neither total AKT nor total ERK are changed. The Y axis indicates the pixel/area.
Figure 6 Effects of a MET inhibitor (PHA-665752) and an FGFR inhibitor (PD-173074) on cell proliferation induced by the addition of
fibroblast culture supernatant. After the addition of 1 μM PD-173074 or 1 μM PHA-665752 to fibroblast (HEF75-hTERT) culture supernatant, cell
proliferation assays were performed. The results for representative cell lines are shown as bar graphs. The Y axis indicates the absorbance.
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fibroblast supernatant is dependent on HGF/MET. The
blunting index for PHA-665752 was 34.15 and 23.60 in
KYSE220 and TE-14, respectively. The blunting index
for PD-173074 was 30.30 and 63.05 in KYSE220 and
TE-14, respectively (Figure 6). These results suggest that
stimulation by fibroblasts is more dependent on HGF/MET
than on FGFs/FGFR in KYSE220, while it is dependent
more on FGF/FGFR than on HGF/MET in TE-14.
Testing all ESCC cell lines for the relative contribution of
HGF/MET and FGF/FGFR in a similar experiment, demon-
strates that four cell lines (KYSE220, TTN, TE-6, and TE-
15) are dependent on HGF/MET, while eight cell lines
(KYSE30, KYSE50, TT, TE-6, TE-9, TE-11, TE-14, and TE-
15) are dependent on FGF/FGFR. These results indicate that
paracrine stimulation by fibroblast is dependent, at least in
part, on HGF/MET or FGF/FGFR. These results also show
that there is diversity among ESCC cell lines with regard to
dependence on HGF/METand FGF/FGFR.
Inhibitory effects of lapatinib on ESCC cell proliferation
and rescue by fibroblast supernatant
Cancer treatment strategies are currently shifting to targeted
therapies. Several drugs are target members of the human
epidermal growth factor receptor (EGFR/HER) family [46].
This family includes four membrane receptor tyrosine ki-
nases, EGFR (HER1/erbB1), HER2 (erbB2), HER3 (erbB3),
and HER4 (erbB4), which activate key cell signaling path-
ways controlling cell growth, proliferation, migration, apop-
tosis, and resistance to cytotoxic agents [47]. Wang et al.
reported that supernatants of human fibroblast cell lines in-
duce gefinitib resistance in lung cancer cell lines [48].Figure 7 The inhibitory effect of lapatinib on the proliferation of 22 c
supernatant against lapatinib-induced inhibition. Lapanitib (1 μM) inhib
lines. Addition of fibroblast supernatant rescues growth inhibition by lapatiIn this study we examined the inhibitory effect of
lapatinib on ESCC cell lines. In addition, we studied
whether the fibroblast supernatants affect the inhibitory
effect of lapatinib on ESCC cell proliferation. The re-
sults are shown in Figure 7. Lapanitib at 1 μM inhibits
cell proliferation by more than 50% in the majority of
the ESCC cell lines. Addition of fibroblast supernatant
rescues growth inhibition by lapatinib and recovers cell
proliferation by 20% or more in 10 cell lines. These find-
ings suggest that fibroblast supernatants might induce
resistance to lapatinib in ESCC cell lines.FGFR inhibitor (PD-173074) blocks the rescue effect of
fibroblast supernatants against lapatinib
Recent studies indicate that paracrine stimuli from stromal
fibroblasts may confer resistance to various molecular tar-
geted agents including lapatinib [49-51]. We reasoned that
blockade of paracrine stimuli may attenuate the rescue ef-
fect of fibroblast supernatant in lapatinib-sensitive ESCC
cell lines. We chose TE-11 and TE-14 cell lines in which
the paracrine effect of fibroblasts are dependent on FGFRs,
and tested the effect of FGFR inhibitor on the rescue effect
of fibroblast supernatant.
The results of these experiments are shown in Figure 8.
Based on a cell count assay, when representative cell lines
were additionally treated with 1 μM of FGFR inhibitor (PD-
173074), together with fibroblast supernatants and 1 μM of
lapatinib, proliferation rates are similar to those obtained
after adding only lapatinib to the cancer cells. These results
show that PD-173074 blocks the rescue effect of fibroblast
supernatants against lapatinib.ancer cell lines and the rescue effect of fibroblast culture
its cell proliferation by more than 50% in the majority of the ESCC cell
nib and recovers cell proliferation by 20% or more in 10 cell lines.
Figure 8 Rescue from lapatinib inhibition by FB-SN and abrogation by FGFR inhibitor. The inhibitory effect of lapatinib on the proliferation
of representative cell lines is rescued by the addition of fibroblast culture supernatant. Further addition of FGFR inhibitor (PD-173074) abrogates
the rescue effect of fibroblast supernatant. The Y axis indicates the absorbance.
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The concentrations of HGF in culture supernatants of
the fibroblasts HEF75, HEF75-hTERT, and HFL-III were
4049 pg/mL, 9390 pg/mL, and 9381 pg/mL, respect-
ively, and the concentrations of FGF7 were 249 pg/mL,
1087 pg/mL, and 17 pg/mL, respectively. Culture super-
natants of HFL-III, a lung-derived fibroblast line, con-
tained high concentrations of HGF, but very low
concentrations of FGF7. The culture supernatants of
measured cancer cells (KYSE30, KYSE50, KYSE150,
KYSE220, T.TN, TE-8, TE-11, TE-14, and TE-15) con-
tained virtually no HGF or FGF7, suggesting that the
autocrine activity of these cells was minimal.
Discussion
The importance of the tumor microenvironment for tumor
growth has been recognized for many years [51]. Cancers
develop in a complex and dynamic microenvironment. Stro-
mal fibroblasts are one of the major stromal components
and it is becoming increasingly clear that fibroblasts are also
prominent modifiers of cancer progression [21].
To date, few studies have comprehensively evaluated the
interactions between ESCC and stromal fibroblasts. We
studied 22 ESCC cell lines, the maximum available commer-
cially, because many previous studies used few cell lines that
were appropriate for the experiments. Furthermore, we iso-
lated esophageal stromal fibroblasts from resected speci-
mens and immortalized a portion of them. These studies
clarify the roles of fibroblasts in the proliferation of ESCC
and in resistance to lapatinib, given the diversity of cancer.
We first examined cell proliferation induced by fibro-
blasts. The addition of fibroblast supernatant induced cell
proliferation in the majority of ESCC cell lines. In particu-
lar, supernatants from immortalized fibroblasts had astronger impact on cancer cell lines. HEF75-hTERT, im-
mortalized fibroblasts, increased cell proliferation by 1.25
fold or more in 21 of 22 cell lines, while normal fibroblasts
increased proliferation in 12 of 22 cell lines (Figure 1).
These results imply that immortalized fibroblasts may de-
velop properties similar to the so-called cancer associated
fibroblasts.
Stromal fibroblasts promote tumor progression in sev-
eral ways such as secretion of multiple factors and
matrix metalloproteinases [52]. We hypothesized that
some growth factors, such as HGF or FGFs secreted by
stromal fibroblasts may be responsible for the prolifera-
tion effect of ESCC cells. In fact, previous studies have
suggested that HGF promotes invasion of ESCC cells
[23] and FGF7 (keratinocyte growth factor: KGF) in-
creases the growth rate of esophageal cancer cell lines
(TE-8 and TE-11) [24]. We next examined the effects of
adding growth factors to the culture medium of cancer
cells and the effects of FGFR inhibitor and MET inhibi-
tor treatment on cell proliferation induced by fibroblast
supernatant. The results of experiments to evaluate the
effects of adding growth factors and kinase inhibitors
suggest that the stimulating effect of fibroblasts was at-
tributable in part to HGF/MET or FGF/FGFR (Figure 4).
The results indicate diversity in the degree of depend-
ence on HGF/MET and FGF/FGFR among the cell lines.
The exogenous proliferation of more ESCC cell lines
may depend on FGF/FGFR signaling rather than on
HGF/MET signaling.
The development of targeted therapies is a major advance
in the treatment of cancer [46], but data for esophageal can-
cer are still lacking [53]. Previous reports imply that targeted
therapy has potential for the treatment of patients with
ESCC [33]. Stromal fibroblasts also might correlate with
Saito et al. BMC Cancer  (2015) 15:82 Page 11 of 12resistance to targeted therapy [49,51]. Lapatinib, which is a
dual tyrosine kinase inhibitor, is considered a promising can-
didate [54]. When we added 1 μM of lapatinib to the 22
ESCC cell lines tested, proliferation was strongly inhibited in
a majority of the cells lines (Figure 7). However, lapatinib-
induced inhibition was abrogated by fibroblast supernatants
in many cell lines, and proliferation in 10 of the 22 cell lines
was rescued more than 25% (Figure 7). These findings sug-
gest that lapatinib inhibits the proliferation of ESCC cells in
an intrinsic manner, while fibroblasts might antagonize the
effect of lapatinib. Moreover, these results imply that the ef-
fect of targeted therapies can be attenuated by stromal fibro-
blasts. Fibroblasts might thus have a role in drug resistance,
even in ESCC cell lines.
Finally, we tested whether the FGFR inhibitor PD-173074
could eliminate the rescue effect against lapatinib that was
induced by fibroblast supernatants. In two representative
cell lines (TE-11 and TE-14), fibroblast supernatant re-
stored the growth of cancer cells inhibited by lapatinib, but
the subsequent addition of PD-173074 abrogated the rescue
effect of fibroblast supernatant against lapatinib (Figure 8).
These findings imply that combination therapy with lapati-
nib and an FGFR inhibitor might be effective in overcoming
therapeutic resistance against to lapatinib caused by stromal
fibroblasts.Conclusions
We studied 22 ESCC cell lines taking into account the di-
versity of malignancies. In more than half of the cancer cell
lines tested, proliferation was induced by culture superna-
tants of immortalized fibroblasts. Growth factors, such as
HGF or FGFs secreted by fibroblasts influence cell prolifer-
ation and resistance to lapatinib in some cancer cell lines,
although the degree of dependence differs among the cell
lines. The addition of fibroblast supernatant attenuates the
effect of lapatinib. However, the rescue effect of fibroblast
supernatant is abrogated by combining an FGFR inhibitor
with lapatinib. Although this study was performed in vitro,
these results may lead to the development of new treatment
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